Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.